PeppiLibrary

Healing

ARA-290 peptide reference

EPO-derived 11-AA peptide. Anti-inflammatory and tissue-protective without erythropoietic effects.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing ARA-290 notes
Default dose label4 mg
Preferred routeSubQ
Frequency label1× daily
Storage window28 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Multiple Phase 2 trials; not yet approved

Investigational

Route map

How records are usually labeled

1 SubQ
2 IV

Rotate within abdomen.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 10 mg vial
Dose 4 mg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for ARA-290. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin (EPO). It binds the innate-repair receptor (IRR — a heterodimer of EPOR and βcR) without activating the classical EPO receptor, decoupling tissue-protective effects from erythropoiesis. Investigated for diabetic neuropathy, sarcoidosis, and chronic-inflammation models.

Also known as: Cibinetide.

Diabetic neuropathy researchSarcoidosis (Phase 2)Chronic inflammation / nerve repair research

Mechanism and timing snapshot

Selective agonist of the innate-repair receptor (IRR), driving anti-inflammatory and tissue-protective signalling. Does not activate the classical EPO receptor — no hematopoietic stimulation, no thrombosis risk.

Onset label30 min
Catalog onset field, when available.
Half-life label3 min
Plasma half-life ~2 minutes; biological effects last hours due to receptor signalling
Duration label24 hr
Catalog duration field, when available.
subQ Moderate
IV High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose4 mg
Catalog dose range1 mg - 8 mg
Default routeSubQ
Frequency label1× daily
Best time labelAnytime, consistent timing.
Food noteNone.

Catalog protocol note

Phase 2 trial dose: 4 mg subQ daily for 28 days; longer courses for chronic conditions.

Routes and site notes

Available route labelsSubQ, IV
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate within abdomen.

Chemistry

SequenceQEQLERALNSS (helix B, 11 AA)
Amino acids11
Molecular formulaC50H81N15O22
Molecular weight1257.27 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size10 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note10 mg in 2 mL → 0.80 mL = 4 mg (80 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Generally well-tolerated
  • Mild injection-site reactions
  • Headache
  • Fatigue

Contraindications and warnings

  • Pregnancy
  • Investigational — not yet approved.
  • Specifically does NOT raise hematocrit — distinct from native EPO.

Other considerations

  • Mechanism is anti-inflammatory tissue-protection, not red-cell stimulation.
  • Promising for neuropathic pain, sarcoidosis, and chronic-inflammation models.
  • Long-term safety in healthy users uncharacterised.

Evidence and regulatory context

Evidence levelMultiple Phase 2 trials; not yet approved
FDA approvedNo
Regulatory statusInvestigational
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteNot listed
Typical cycle label4–12
Typical break label4
Cycle guidanceCourse-based for inflammatory conditions; longer continuous use for neuropathy in trials.

Tracking tips

  • Does not raise hematocrit — mechanism is decoupled from native EPO erythropoiesis.
  • Best evidence is in diabetic small-fibre neuropathy.
  • Investigational; long-term healthy-user data is sparse.

References

Track it in Peppi

Keep ARA-290 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for ARA-290?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use ARA-290?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export ARA-290 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026